Angelman Syndrome Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

Angelman Syndrome Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

Delveinsight Business Research
DelveInsight’s “Angelman Syndrome Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Angelman Syndrome, historical and forecasted epidemiology as well as the Angelman Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Angelman syndrome (AS) is a complex genetic disorder that primarily affects the nervous system. The characteristic features of this condition include delayed development, intellectual disability, severe speech impairment, and problems with movement and balance (ataxia). Most affected children also have recurrent seizures (epilepsy) and a small head size (microcephaly).

It is caused by a variety of genetic abnormalities involving the chromosome 15q11-13 region, which is subjected to genomic imprinting. These include maternal deletion, paternal uniparental disomy, imprinting defects, point mutations or small deletions within the UBE3A gene, which lies within this region.

Delayed development becomes noticeable by the age of 6 to 12 months, and other common signs and symptoms usually appear in early childhood. Children with Angelman syndrome experience delays in reaching developmental milestones (developmental delays) and have severe learning disabilities. Angelman syndrome affects males and females in equal numbers.


Get FREE sample copy at:



The Angelman Syndrome market report also covers emerging drugs, current treatment practices, Angelman Syndrome market share of the individual therapies, current and forecasted Angelman Syndrome Market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Angelman Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. 


Angelman Syndrome Market Key Facts

The total prevalent population of Angelman syndrome in the 7 major markets was 58,351 in 2017 which constituted both live-birth cases as well as adult prevalent cases .

The estimated prevalence of Angelman syndrome in the United States with 21,996 cases in 2017.

Among the EU5 countries, Germany had the highest prevalent population of Angelman syndrome with 6,671 cases and Spain had the lowest prevalent population of 3,761 cases in 2017.

The United States accounts for the largest market size of Angelman syndrome, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.


Key Benefits of Angelman Syndrome Market Report

  • Angelman Syndrome market report provides an in-depth analysis of Angelman Syndrome Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.

  • The Angelman Syndrome market report will help in developing business strategies by understanding the Angelman Syndrome Market trends & developments, key players and future market competition that will shape and drive the Angelman Syndrome market in the upcoming years.

  • The Angelman Syndrome market report covers Angelman Syndrome current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Angelman Syndrome market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 


Angelman Syndrome Market

The Angelman Syndrome market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Angelman Syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. 

The report gives a thorough detail of Angelman Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 


Angelman Syndrome Epidemiology

The Angelman Syndrome epidemiology section covers insights about historical and current Angelman Syndrome patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  


Angelman Syndrome Drugs Uptake and Key Market Players

The Angelman Syndrome Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Angelman Syndrome market or expected to get launched in the market during the study period. The analysis covers Angelman Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The pipeline for Angelman Syndrome is not robust. To counter current unmet needs of the market and to provide better treatment options for Angelman syndrome. With the ongoing research studies at both industry and university level, the future of Angelman syndrome treatment seems promising. 

Some of the key players in the Angelman Syndrome market includes:
Ovid Therapeutics
GeneTx Biotherapeutics
PTC Therapeutics
Sarepta Therapeutics
And others.


Drugs Covered
Gaboxadol (OV101)
GTX-101 and GTX-102
And many others.


Table of Content

1. Key Insights

2. Executive Summary 

3. Angelman Syndrome Competitive Intelligence Analysis

4. Angelman Syndrome Market Overview at a Glance

5. Angelman Syndrome Disease Background and Overview

6. Angelman Syndrome Patient Journey

7. Angelman Syndrome Epidemiology and Patient Population

8. Angelman Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Angelman Syndrome Unmet Needs

10. Key Endpoints of Angelman Syndrome Treatment

11. Angelman Syndrome Marketed Products

12. Angelman Syndrome Emerging Therapies

13. Angelman Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. Angelman Syndrome Market Outlook (7 major markets)

16. Angelman Syndrome Access and Reimbursement Overview

17. KOL Views on the Angelman Syndrome Market.

18. Angelman Syndrome Market Drivers

19. Angelman Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer


Related Reports

Angelman Syndrome Epidemiology Forecast to 2030

DelveInsight’s ‘Angelman Syndrome Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Angelman Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States